VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Kymera Therapeutics Executive Compensation (FY25)

KYMR · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Nello Mainolfi
Latest say-on-pay support
=
June 24, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Kymera Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 4, 2026Latest filing (8-K): June 24, 2026
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Kymera Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
270 figures on this page: 265 cited to the filing that reported them, 5 calculated from figures it prints. See the citations

More on Kymera Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Nello Mainolfi: $15,433,147 → $8,545,609 (44.6% lower)
CEO pay ratio: 39:1 → 21:1 (46.2% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Kymera Therapeutics' chief executive and what were they paid?
Nello Mainolfi, Founder, President and Chief Executive Officer, received $8,545,609 in total compensation for fiscal 2025. Mainolfi's total moved 44.6% lower from the $15,433,147 reported for fiscal 2024.
What was Kymera Therapeutics' say-on-pay result?
Shareholders recorded 96.8% support for the say-on-pay proposal at the meeting held June 24, 2026 for fiscal 2025.
Which companies are in Kymera Therapeutics' peer group?
The disclosed peer group includes ApogeeTherapeutics, Arcellx, Avidity Biosciences, Beam Therapeutics and Biohaven, among others.
What is Kymera Therapeutics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 21:1, against median employee compensation of $409,607.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nello Mainolfi
Founder, President and Chief Executive Officer
◇——◇◇—◇◇
Bruce Jacobs
Chief Financial Officer
◇—◇◇◇—◇◇
Jared Gollob
Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nello Mainolfi
Founder, President and Chief Executive Officer
◇——◇◇—◇◇
Jeremy Chadwick
Chief Operating Officer
◇—◇◇◇—◇◇
Ellen Chiniara
Chief Legal Officer
◇—◇◇◇—◇◇
Bruce Jacobs
Chief Financial Officer
◇—◇◇◇—◇◇
Jared Gollob
Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nello Mainolfi
Founder, President and Chief Executive Officer
◇——◇◇—◇◇
Bruce Jacobs
Chief Financial Officer
◇—◇◇◇—◇◇
Jared Gollob
Chief Medical Officer
◇—◇◇◇—◇◇
Ellen Chiniara
Chief Legal Officer
◇—◇◇◇—◇◇
Jeremy Chadwick
Chief Operating Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nello Mainolfi
Founder, President and Chief Executive Officer
◇——◇◇—◇◇
Brian Adams
Chief Legal Officer
◇—◇◇◇—◇◇
Noah Goodman
Chief Business Officer
◇—◇◇◇—◇◇
Jared Gollob
Chief Medical Officer
◇—◇◇◇—◇◇
Bruce Jacobs
Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brian AdamsRSU◇——◇——◇
Brian AdamsOPTION◇——◇—◇◇
Bruce JacobsRSU◇——◇——◇
Bruce JacobsOPTION◇——◇—◇◇
Jared GollobRSU◇——◇——◇
Jared GollobOPTION◇——◇—◇◇
MBAOPTION◇——◇—◇◇
MBARSU◇——◇——◇
Nello MainolfiOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Nello MainolfiOption◇—◇3/2/2035
Option◇—◇2/28/2034
Option◇—◇3/2/2035
RSU◇◇——
Option◇—◇2/28/2033
Brian AdamsOption◇—◇9/2/2035
RSU◇◇——
Noah GoodmanOption◇—◇4/7/2035
RSU◇◇——
Bruce JacobsOption◇—◇2/28/2034
Option◇—◇3/2/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/28/2033
RSU◇◇——
Jared GollobOption◇—◇2/28/2034
Option◇—◇3/2/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/28/2033
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Brian Adams
Chief Legal Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Bruce Jacobs
Chief Financial Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Jared Gollob
Chief Medical Officer · Employment agreement
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Nello Mainolfi
Founder, President and Chief Executive Officer · Employment agreement
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Noah Goodman
Chief Business Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bruce Booth
◇—◇———◇
Jeffrey Albers
◇—◇———◇
Felix J. Baker
◇—◇———◇
Elena Ridloff
◇—◇———◇
Pamela Esposito
◇—◇———◇
John Maraganore
◇—◇———◇
Gorjan Hrustanovic Ph.D
◇—◇———◇
Victor Sandor
◇—◇———◇
Leigh Morgan
◇—————◇
Nello Mainolfi served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ApogeeTherapeutics symbol not shown
  • Arcellx ACLX
  • Avidity Biosciences RNA
  • Beam Therapeutics BEAM
  • Biohaven BHVN
  • Denali Therapeutics DNLI
  • Dyne Therapeutics DYN
  • IDEAYA Biosciences IDYA
  • ImmunityBio IBRX
  • Immunovant IMVT
  • Nuvalent NUVL
  • Protagonist Therapeutics PTGX
  • Vaxcyte PCVX
  • Vera Therapeutics VERA
  • Viking Therapeutics VKTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 24, 2026=◇◇◇
2024June 25, 2025=◇◇◇
2023June 18, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 15, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Nello Mainolfi (Founder, President and Chief Executive Officer), FY2025 total compensation $8,545,609 (base salary $693,000) [exec_comp, SEC accession 0001193125-26-191495, filed 2026-04-29]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Kymera Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Kymera Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Kymera Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Kymera Therapeutics' disclosed peer group is defensible, who names Kymera Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
270 figures on this page: 265 cited to the filing that reported them, 5 calculated from figures it prints.
265 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001193125-26-281051
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-191495
    2025 Summary Compensation Table · Compensation Discussion and Analysis · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · and 1 more section
  3. 0001193125-25-151345
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001193125-25-103767
  5. 0001193125-24-164550
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-24-110064
  7. 0001193125-23-168977
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-22-175498
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Kymera Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/KYMR (accessed 2026).
Short form: data: Velarion

The paid brief for Kymera Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Kymera Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Kymera Therapeutics discloses

The companies named in KYMR's own disclosed peer group.

ArcellxAvidity BiosciencesBeam TherapeuticsBiohavenDenali TherapeuticsDyne TherapeuticsIDEAYA BiosciencesImmunityBioImmunovantNuvalentProtagonist TherapeuticsVaxcyteVera TherapeuticsViking Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy